| Trial ID # | NCT02901899 |
| Phase | II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-1 |
| Drug Name | Pembrolizumab |
| Alternate Drug Names | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 |
| Drugs in Trial | Guadecitabine, Pembrolizumab |
| Eligible Participant | Platinum resistant ovarian cancer |
| Patients Enrolled | 43, median 4 prior therapies (1-8) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, PFS |
| Efficacy | ORR: 9.1% (3PR, n=33) |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | Pembrolizumab+guadecitabine has modest activity but some patients experience prolonged disease stabilization |
| Reference | Matei D et al. Phase II trial of guadecitabine priming and pembrolizumab in platinum resistant recurrent ovarian cancer. J Clin Oncol (2020) 38: (suppl; abstr 6025) https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.6025 Matei D et al. Poster |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.